BNP PARIBAS FINANCIAL MARKETS - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 137 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$16,715,056
-7.1%
320,888
+13.0%
0.02%
-4.5%
Q2 2023$17,985,349
+76.3%
284,039
+50.8%
0.02%
+57.1%
Q1 2023$10,202,726
+186.3%
188,416
+179.8%
0.01%
+180.0%
Q4 2022$3,563,844
-99.9%
67,344
+25.4%
0.01%
+25.0%
Q3 2022$2,499,312,000
+2.7%
53,714
+26.0%
0.00%0.0%
Q2 2022$2,432,978,000
+97.5%
42,624
+111.7%
0.00%
+100.0%
Q1 2022$1,231,938,000
+57.5%
20,133
+34.7%
0.00%
+100.0%
Q4 2021$782,169,000
+65.8%
14,944
+18.1%
0.00%0.0%
Q3 2021$471,741,000
+336.4%
12,654
+377.9%
0.00%
Q2 2021$108,091,000
-84.3%
2,648
-87.0%
0.00%
-100.0%
Q1 2021$689,322,000
+67.2%
20,316
+56.7%
0.00%0.0%
Q4 2020$412,287,000
+4.4%
12,965
-15.8%
0.00%0.0%
Q3 2020$394,882,000
+334.1%
15,389
+334.2%
0.00%
Q2 2020$90,974,000
-65.2%
3,544
-79.2%
0.00%
-100.0%
Q1 2020$261,751,000
+22.4%
17,030
+173.2%
0.00%
Q4 2019$213,854,000
+252.6%
6,233
-23.2%
0.00%
Q3 2019$60,656,000
-22.4%
8,120
+34.9%
0.00%
Q2 2019$78,127,000
-38.1%
6,019
-41.9%
0.00%
Q1 2019$126,197,000
+951.2%
10,361
+883.0%
0.00%
Q4 2018$12,005,000
-78.4%
1,054
-58.9%
0.00%
Q3 2018$55,682,000
+32.7%
2,566
+8.1%
0.00%
Q2 2018$41,949,000
-77.2%
2,374
-72.8%
0.00%
Q1 2018$183,956,000
+13.3%
8,739
-22.0%
0.00%
Q4 2017$162,321,000
+145.1%
11,210
+167.2%
0.00%
Q3 2017$66,213,000
+20.1%
4,196
-5.5%
0.00%
Q2 2017$55,132,000
+348.8%
4,439
+487.2%
0.00%
Q1 2017$12,285,000
-25.7%
756
-31.0%
0.00%
Q4 2016$16,539,000
-71.3%
1,096
-71.1%
0.00%
Q3 2016$57,714,000
+11.9%
3,787
+185.0%
0.00%
Q2 2016$51,592,000
-80.7%
1,329
-73.3%
0.00%
-100.0%
Q4 2015$267,874,000
+48.0%
4,980
+10.2%
0.00%
Q3 2015$181,021,000
+213.9%
4,521
+150.5%
0.00%
Q2 2015$57,670,000
+506.8%
1,805
+353.5%
0.00%
Q1 2015$9,504,000
-32.2%
398
-61.1%
0.00%
Q3 2014$14,025,0001,0230.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2019
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders